ReviewNeurobiology of disease2009
Chipping away at diagnostics for neurodegenerative diseases.
Review in Neurobiology of disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.Science translational medicine · 2010Pooled it
- Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.Proceedings of the National Academy of Sciences of the United States of America · 2011Trial
- Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease.Frontiers in aging neuroscience · 2018Article
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.Annals of neurology · 2016Article
- Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker study.Neurology · 2014Article
- Metallothioneins as dynamic markers for brain disease in lysosomal disorders.Annals of neurology · 2014Article
- Neurodegeneration as an RNA disorder.Progress in neurobiology · 2012Review
- Age-related changes of gene expression in the neocortex: preliminary data on RNA-Seq of the transcriptome in three functionally distinct cortical areas.Development and psychopathology · 2012Article
- Article
- Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2010Article
- Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.Nature medicine · 2010Article
- Deep sequencing of coding and non-coding RNA in the CNS.Brain research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Biomarkers are needed to overcome critical roadblocks in the development of disease-modifying therapeutics for neurodegenerative diseases. Evolving genome-wide expression technologies can comprehensively search for molecular biomarkers and allow fascinating insights into the expanding complexity of the human transcriptome. The technology has matured to the point where some applications are deemed reliable enough for use in patient care. In the neurosciences, it has led to the discoveries of osteopontin in multiple sclerosis and SORL1/LR11 in Alzheimer's, and recent studies indicate its potential for identifying neurogenomic biomarkers. Advances in pre-analytical and analytical methods are improving search efficiency and reproducibility and may lead to a pipeline of biomarker candidates suitable for development into future neurologic diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.